XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.15

+2.8%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (10650)	7/7/1999 7:15:00 PM
From: Pseudo Biologist	Read Replies (2) of 17367

George, you got it right re. disclosure. Biogen did release some data to some people as evidenced by the following post that cites a Salomon-Smith Barney report: Message 9842622 Here is the most interesting part: ******************************************** Biogen announced positive results from its Phase IIb trial of Amevive for moderate to severe psoriasis. The trial was a randomized placebo controlled study with 229 patients in four arms, 3 dose arms of Amevive and one placebo arm. Patients received IV bolus injections once weekly for 12 weeks, with 12 weeks of follow-up. Results: The primary end-point was efficacy at 2 weeks after completion of the 12 week dosing. The drug worked quickly, with initial effect noted 2-4 weeks after initiation of therapy. At 2 weeks post-treatment, over 50% of patients in the top 2 dose groups had improvements vs 20% in the placebo group. The physician global assessment of the disease improved to mild or better in 37% of Amevive-treated patients vs 11% of placebo patients. At 2-weeks post-treatment, 20% of Amevive patients had complete clearance vs 0% of placebo patients. At 3 months post-treatment, 23% of Amevive-treated patients were still clear or almost clear, vs 0% of placebo patients. The results were statistically significant. Safety: There was a modest reduction of T cell count, which did not go below the lower limit of normal for most patients and was reversible upon discontinuation of treatment. No capillary leak or cytokine release syndrome was detected ************************** Hard to say from here that these numbers are any better or any worse than Xoma/Genentech's molecule. Do you know anything about "Olux"? PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next